The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment.
In spite of a substantial increase in the use of bisphosphonates at child bearing age, very little is known regarding its use in pregnancy. We describe the outcome of 24 pregnancies after pre-pregnancy or early pregnancy alendronate therapy. Based on the pregnancy outcome it seems that alendronate does not impose a major teratogenic risk.
Ornoy
Asher
A
The Israeli Teratogen Information Service, Laboratory of Teratology, Hebrew University Hadassah Medical School, Israeli Ministry of Health, Jerusalem, Israel. ornoy@cc.huji.ac.il
Wajnberg
Rivka
R
Diav-Citrin
Orna
O
D000328:Adult; D019386:Alendronate / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy; D001528:Behcet Syndrome / Q000188:drug therapy; D001607:Berylliosis / Q000188:drug therapy; D001835:Body Weight / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy; D005260:Female; D005865:Gestational Age; D019693:Hepatitis, Autoimmune / Q000188:drug therapy; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy; D046150:Laron Syndrome / Q000188:drug therapy; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy; D016878:POEMS Syndrome / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011256:Pregnancy Outcome; D011261:Pregnancy Trimester, First; D012042:Registries / Q000706:statistics & numerical data
D050071:Bone Density Conservation Agents; D019386:Alendronate